Active Studies

The purpose of this study is to evaluate the safety and pharmacokinetics ASG-22CE as well as
assess the immunogenicity and antitumor activity in subjects with metastatic urothelial
cancer and other malignant solid tumors.

This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for
patients with advanced colorectal cancer that no longer responds to standard therapies.

The treatment is being evaluated for its effect on tumor growth. It consists of small beads
that contain mouse cancer cells from a mouse kidney cancer cell line. The cells in the beads
produce substances that have been shown to slow or stop the growth of tumors in experimental
animals, veterinary patients, and 37 humans with colorectal cancers in a Phase 1 and 2
safety trials.

This randomized phase II/III trial studies how well pazopanib hydrochloride, combination
chemotherapy, and radiation therapy work and compares it to radiation therapy alone or in
combination with pazopanib hydrochloride or combination chemotherapy in treating patients
with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by
surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in
chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. It is not yet known whether
radiation therapy works better when given with or without combination chemotherapy and/or
pazopanib hydrochloride in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.

This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole,
letrozole, or exemestane with or without chemotherapy work in treating patients with breast
cancer that has spread from where it began in the breast to surrounding normal tissue
(invasive). Estrogen can cause the growth of breast cancer cells. Hormone therapy, using
tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor
cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight
breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy
work in different ways to stop the growth of tumor cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. It is not yet known whether
giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective with
combination chemotherapy in treating patients with breast cancer.

This randomized phase III trial studies standard or comprehensive radiation therapy in
treating patients with early-stage breast cancer who have undergone surgery. Radiation
therapy uses high-energy x rays to kill tumor cells. It is not yet known whether
comprehensive radiation therapy is more effective than standard radiation therapy in
treating patients with breast cancer

Pages